Skip to main content

Table 1 Distribution of the responses in the 28-day trial

From: Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon

Year Treatment Number included Parasite clearance on day 3 (ITT) (%) Observed ACPR Lost to follow-up and excluded Reinfection ITT1 PP1
2005 AQ 64 87.5 50 5 5 50/64
(55/64)
50/59
(55/59)
  AS-AQ 60 100 43 6 10 43/60
(53/60)
43/54
(53/54)
  AS-SP 61 96.8 50 4 4 50/61
(54/61)
50/57
(54/57)
2006a AQ-SP 67 86.6 55 5 7 55/67
(62/67)
55/62
(62/62)
  AS-MQ 69 95.7 60 8 1 60/69
(61/69)
60/61
(61/61)
2006b AS-AQ 62 98.4 52 5 3 52/62
(55/62)
52/57
(55/57)
  AM-LM 61 100 58 1 2 58/61
(60/61)
58/60
(60/60)
2006c AS-CD 83 97.6 53 12 7 53/83
(60/83)
53/71
(60/71)
  AS-SP 85 100 73 6 1 73/85
(74/85)
73/79
(74/79)
2007 AS-AQ 92 99 73 4 8 73/92
(81/92)
73/88
(81/88)
  DH-PP 91 100 84 5 0 84/91
(84/91)
84/86
(84/86)
  1. 1Values in parentheses denote the observed proportions of ACPR after PCR correction in each treatment group. No recrudescence was observed with the AM-LM combination, and no re-infection was observed with DH-PP. ITT, intention-to-treat; PP, per protocol.